Cardiol Therapeutics (TSE:CRDL) Shares Up 1.3% – Should You Buy?

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) rose 1.3% during trading on Thursday . The stock traded as high as C$1.56 and last traded at C$1.51. Approximately 48,612 shares were traded during mid-day trading, a decline of 50% from the average session volume of 97,890 shares. The stock had previously closed at C$1.49.

Cardiol Therapeutics Price Performance

The company has a market cap of C$174.06 million, a P/E ratio of -3.87 and a beta of 0.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.84 and a current ratio of 4.39. The business’s fifty day moving average is C$1.73 and its two-hundred day moving average is C$1.56.

Cardiol Therapeutics (TSE:CRDL) last issued its earnings results on Monday, May 11th. The company reported C($0.10) EPS for the quarter. Equities analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.